Quality of life and psychological functioning in postmenopausal women undergoing aromatase inhibitor treatment for early breast cancer

Autor: Gabriella Martino, Rita Maria Agostino, Nunziata Morabito, Antonino Catalano, Federica Bellone, Carmelo M. Vicario, Peter Schwarz, Carmen Lasco, Ulla Feldt-Rasmussen
Jazyk: angličtina
Rok vydání: 2020
Předmět:
Critical Care and Emergency Medicine
Hamilton Anxiety Rating Scale
Emotions
Osteoporosis
Cancer Treatment
Social Sciences
Anxiety
Biochemistry
Severity of Illness Index
Body Mass Index
0302 clinical medicine
Quality of life
Bone Density
Breast Tumors
Medicine and Health Sciences
Psychology
Enzyme Inhibitors
Vitamin D
Trauma Medicine
Multidisciplinary
Anxiety/pathology
Depression
Aromatase Inhibitors
Middle Aged
Postmenopause
Oncology
Bone Fracture
Vitamin D/blood
030220 oncology & carcinogenesis
Medicine
Female
Traumatic Injury
Research Article
medicine.medical_specialty
Psychometrics
medicine.drug_class
Science
Breast Neoplasms
03 medical and health sciences
Breast cancer
Internal medicine
Mental Health and Psychiatry
Breast Cancer
Severity of illness
medicine
Humans
Aged
Aromatase inhibitor
Mood Disorders
business.industry
Beck Depression Inventory
Biology and Life Sciences
Cancers and Neoplasms
Breast Neoplasms/diagnosis
medicine.disease
Health Surveys
Case-Control Studies
Depression/pathology
Enzymology
Quality of Life
business
Body mass index
030217 neurology & neurosurgery
anxiety
depression
chronic diseases
breast cancer
aromatase inhibitors
osteoporosis
Aromatase Inhibitors/therapeutic use
Zdroj: Martino, G, Catalano, A, Agostino, R M, Bellone, F, Morabito, N, Lasco, C G, Vicario, C M, Schwarz, P & Feldt-Rasmussen, U 2020, ' Quality of life and psychological functioning in postmenopausal women undergoing aromatase inhibitor treatment for early breast cancer ', PLoS ONE, vol. 15, no. 3, e0230681 . https://doi.org/10.1371/journal.pone.0230681
PLoS ONE
PLoS ONE, Vol 15, Iss 3, p e0230681 (2020)
DOI: 10.1371/journal.pone.0230681
Popis: INTRODUCTION: Aromatase inhibitors (AIs) dramatically increased breast cancer (BC) survival, leading to enhanced attention to their long-term consequences on psychological functioning. Conflicting data has been examined regarding the association between AIs administration and the clinical psychological features in BC survivors (BCSs).PURPOSE: As psychological symptoms often occur in such chronic diseases, our study aimed at exploring anxious and depressive symptoms and the perceived quality of life (QoL) in BCSs assessed for osteoporosis.METHODS: The total sample consisted of a clinical sample of 51 outpatient postmenopausal women, diagnosed with BC, and a control group composed of 51 healthy postmenopausal women. All recruited participants were evaluated through the clinical gold standard interview and completed the following self-rating scales: the Hamilton Anxiety Rating Scale, Beck Depression Inventory II edition, and 36-Item Short Form Health Survey, which were administered at baseline and after 6 months in BCSs in AIs treatment, compared with controls. Moreover, all participants were assessed for vitamin D status, bone mineral density (BMD) and subclinical vertebral fractures. Data regarding age, age at menopause, body mass index (BMI), smoking habits and alcohol consumption was collected.RESULTS: BCSs (n = 51) showed higher anxious and depressive symptoms, and lower perceived QoL vs. controls (n = 51) (pCONCLUSIONS: The improvement of clinical psychological features and perceived QoL was associated with AIs treatment in women being treated with, for early breast cancer. Further studies are needed to obtain a deeper comprehension of the correlation between clinical psychological and physical features in BCSs.
Databáze: OpenAIRE
Externí odkaz: